You are here: Home: Meet The Professors Vol. 2 2004: Case 7: Select publications
 |
Select publications |
 |
Franco S et al. Fulvestrant (FaslodexR) demonstrates clinical benefit in heavily pretreated postmenopausal women with advanced breast cancer: a single-center experience. Breast Cancer Res Treat 2003; Abstract 439.
Howell A et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004;22(9):1605-13. Abstract
|